Study procedures
ADVERSE EVENTS, BLOOD
Non-ICU and ER patients are screened remotely by research staff using the Epic Medical Records system to identify potential study candidates. Patients with a qualifying blood KA physician listed on the consent form will perform a final criteria review and obtain signed informed consent. These study investigators include hospitalists, ER physicians, and nephrologists. To ensure that the patient and primary treating provider are blinded to the study drug, a nephrologist (WLL) will order the study drug that is dispensed by the Investigational Drug Services Pharmacy. The nurse dispending the study drug is advised not to disclose name of study drug to the participant.Blood chemistries including basic metabolic panel, MgFlowchart of study proceduresAn independent Data & Safety Monitoring Board will review potential adverse events every 3 months, or sooner if necessary. This data monitoring committee is comprised of a nephrologist, cardiologist and biostatistician who are not involved in the trial and have no conflict of interest pertaining to the study drugs.